Drugs / MTI-31
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03125746 | Jun 2017 → Oct 2021 | breast cancer | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTI-31 | “We aimed to investigate efficacy and mechanism of MTI-31 (LXI-15029), a novel mTORC1/mTORC2 inhibitor currently in human trial (NCT03125746), in” PMID 30796032 ↗ Feb 2019 |
| Known as | LXI-15029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03125746 ↗ |
| Known as | SCC-31 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594431 ↗ |
| Action | Inhibit | “an mTORC1/2 dual inhibitor” PMID 38057772 ↗ Dec 2023 |
| Modality | Small molecule | — CHEMBL4594431 ↗ |
| Route | Oral | “can be administered orally” NCT03125746 ↗ |
| Target | MTOR | “an mTORC1/2 dual inhibitor” PMID 38057772 ↗ Dec 2023 |